The New York restaurant industry is slowing down, adding fewer jobs and shedding eateries amidst recent hikes in the minimum wage. The Empire State lost 1,000 restaurants last year and the number of jobs as cooks, servers and dishwashers grew by an anemic 1.4 percent. That’s a far cry from the 4.4 percent annual growth...
NYS Entity Status
NYS Filing Date
FEBRUARY 10, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - EMPIRE STATE DEVELOPMENT FUND LLC
AROUND THE WEB
- Restaurant workers feeling the pinch in New York
By Lisa Fickenscher - Friday Jun 23, 2017
- Fit City: Taking Night-Life Cue, Gyms Lower the Lights
By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017
- Athenex IPO Raises $66M to Fund Clinical Trials for Cancer Drugs
By Frank Vinluan - Wednesday Jun 14, 2017
The IPO window is still open for clinical-stage drug companies, and Athenex is now the latest one to pass through it. The cancer drug developer raised $66 million through a public stock offering on Wednesday, funding that the company will devote mostly to a pair of cancer drugs in late-stage clinical development. Athenex priced its […]
- North Korea Accuses U.S. of ‘Mugging’ Its Diplomats in New York
By CHOE SANG-HUN - Sunday Jun 18, 2017
Officials returning from a United Nations conference were about to board a plane when federal agents seized a package they were carrying.
- Five Sites of New York’s L.G.B.T. History
Monday Jun 19, 2017
Jacob Riis Park, a Manhattan church, the Bum Bum Bar and more. In 360 degrees, visit five sites that helped shape New York City’s L.G.B.T. community and its history.
- ‘I’d Be Hurt and Upset’: Cities Fear Trump’s Cuts to Urban Programs
By YAMICHE ALCINDOR - Friday Mar 17, 2017
President Trump’s proposed cuts to the Department of Housing and Urban Development would eliminate programs cities have used to fund things like Meals on Wheels.
- Protagonist, Janssen Ink Development Deal for Crohn’s Disease Drug
By Frank Vinluan - Tuesday May 30, 2017
Protagonist Therapeutics’ work developing an inflammatory bowel disease drug that can be taken as a pill, rather than injected, now has fresh cash and the backing of a large pharmaceutical partner. Newark, CA-based Protagonist (NASDAQ: PTGX) has entered a partnership with Janssen Biotech to develop and commercialize its drug, PTG-200. Janssen is paying Protagonist $50 […]
- Pride 2017: New York’s L.G.B.T.Q. Story Began Well Before Stonewall
By LIAM STACK - Monday Jun 19, 2017
The gay bar’s 1969 patron-police battle, hailed as a starting point, actually followed many events in the city, now mapped in a sites project.